PROM1 and metastatic malignant neoplasm in the lymph nodes: Consistent with this notion, a higher percentage of CD133+/EpCAM+ CSCs that express PD-L1 were observed in the lymph nodes of NSCLC patients with lymph node metastasis when compared with patients without lymph node metastasis (36).